| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Citra is a health solutions company providing a one-contract, connected solution for clinical, financial and administrative requirements. Solving for the needs of providers, payers, health systems and employers in the transition to value-based care, Citra empowers clients with proven technology, population health, analytics, care management, and administrative services to strategically expand market opportunity, diversify revenue streams, and lower the cost of care and improve quality. Serving 6 of the top 7 Health Plans; 7 Fortune 500 Companies; 50+ IPAs and MSOs managing commercial, Medicare and Medicaid populations; 100+ Provider Groups, Hospitals, Universities and Integrated Delivery Networks throughout the United States and in Puerto Rico. Citra delivers technology and services resulting in more efficient operations and higher quality care. Our vision is for providers, health systems, payers, and employers to embrace the transformation of healthcare payment models using our cohesive clinical, financial and administrative solutions.ical, financial and administrative solutions.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Master Train Inc is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.